Theralase Technologies Inc. (TSXV:TLT)

Market Cap	47.27M
Revenue (ttm)	1.03M
Net Income (ttm)	-4.26M
Shares Out	248.81M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,200
Average Volume	122,873
Open	0.1900
Previous Close	0.1900
Day's Range	0.1900 - 0.1900
52-Week Range	0.1400 - 0.3800
Beta	1.20
RSI	32.66
Earnings Date	Mar 27, 2025

About Theralase Technologies

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develop...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Roger Dumoulin-White
• Employees: 20
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: TLT

Financial Performance

In 2024, Theralase Technologies's revenue was 1.03 million, a decrease of -3.45% compared to the previous year's 1.07 million. Losses were -4.26 million, -6.89% less than in 2023.